Manager TitleAgeSince
Chief Operating Officer - 14/11/2022
Director TitleAgeSince
Director/Board Member 61 16/08/2005
Chairman 67 19/09/2014
Director/Board Member 55 05/06/2008
Change 5-day change 1-year change 3-year change Capi.($)
-23.37%-37.69% - - 12.81L
-7.17%-4.39%+45.51%+79.00% 5.21TCr
+0.24%-1.54%+53.22%+71.85% 5.38TCr
+0.80%-6.31%+3.98%+423.29% 2.35TCr
-0.09%-0.01%-17.62%-14.67% 2.31TCr
-5.95%-2.58%+30.67%-9.58% 1.94TCr
-1.14%+0.03%+31.57%-30.42% 1.76TCr
-5.16%-7.00%+168.44%+306.37% 1.52TCr
-6.91%-5.83%+26.53%+636.97% 1.48TCr
+0.43%-1.03%+24.63%+191.40% 1.41TCr
Average -4.83%-2.62%+40.77%+183.80% 2.6TCr
Weighted average by Cap. -2.80%-2.36%+40.12%+144.11%
Logo 4SC AG
4Sc AG is a Germany-based clinical-stage biopharmaceutical company that develops small-molecule drugs that target key indications in cancer through epigenetic mechanisms. The Company’s product pipeline includes several anti-cancer drugs, which are in various stages of preclinical and clinical development. Its main products are Resminostat, an orally administered histone deacetylase (HDAC) inhibitor for the treatment of a broad spectrum of oncology indications, both in monotherapy in combination with other anti-cancer drugs; 4SC-202, an orally administered small molecule and epigenetic modulator that inhibits the enzymes lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) 1, 2, 3, and 4SC-208, a small molecule that targets two kinases for Hedgehog/GLI signaling.
Employees
14